We are live on ! Find out more
FV2GP

Flagship Ventures 2007 General Partner Portfolio holdings

AUM $107M
This Fund
S&P 500
This Quarter Est. Return
+58.4%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$228M
AUM Growth
+$71.1M
Cap. Flow
-$13M
Cap. Flow %
-5.7%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
CARM
Carisma Therapeutics
CARM
+$28.6M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$25.8M
2
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 79.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
1
Agios Pharmaceuticals
AGIO
$2.36B
$151M 66.31%
3,860,738
– –
RCPT
2
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$42.4M 18.62%
1,011,911
-600,000
-37% -$25.8M
CARM
3
DELISTED
Carisma Therapeutics
CARM
$31M 13.58%
+95,350
New +$28.6M
BGMD
4
DELISTED
BG MEDICINE INC COM STK NEW
BGMD
$3.39M 1.49%
441,072
– –
TTPH
5
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-58,289
Closed -$15.8M

Similar funds

EIGI
Elmrox Investment Group IM New York $107M AUM
BPV
Battery Partners VII Boston, Massachusetts $108M AUM 8.59% 1-Year Est. Return
HDE
Hutner Daniel Ellsworth $117M AUM
WCM
Weyland Capital Management Portsmouth, New Hampshire $94M AUM 1.28% 1-Year Est. Return
NCM
Newgate Capital Management Greenwich, Connecticut $121M AUM 3.73% 1-Year Est. Return
WCM
Wesley Capital Management New York $86M AUM 10.39% 1-Year Est. Return
EGA
Emerging Global Advisors New York $140M AUM 5.42% 1-Year Est. Return
TAG
Tactical Allocation Group Birmingham, Michigan $62.6M AUM 2.17% 1-Year Est. Return

Flagship Ventures 2007 General Partner's Q1 2014 Portfolio in Review

As of Q1 2014, Flagship Ventures 2007 General Partner held 5 positions worth $228M, up 45% from $157M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Flagship Ventures 2007 General Partner withdrew a net $13M in Q1 2014, closing 1 position and reducing 1 holding. Its most notable exit was Tetraphase Pharmaceuticals, Inc., an estimated $15.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 59% a quarter earlier.

Against the trend, Flagship Ventures 2007 General Partner opened a new position in Carisma Therapeutics worth $31M.

  • Flagship Ventures 2007 General Partner's largest Q1 2014 buy was Carisma Therapeutics: 95,350 shares worth $31M.
  • Flagship Ventures 2007 General Partner's biggest Q1 2014 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $25.8M.
  • Flagship Ventures 2007 General Partner fully exited Tetraphase Pharmaceuticals, Inc. in Q1 2014, selling an estimated $15.8M.
  • Flagship Ventures 2007 General Partner's ten largest holdings make up 100% of its $228M portfolio in Q1 2014.
  • Flagship Ventures 2007 General Partner opened 1 new position and closed 1 in Q1 2014.
  • Flagship Ventures 2007 General Partner's portfolio value rose 45% quarter-over-quarter to $228M.

Based on Flagship Ventures 2007 General Partner's 13F filing for Q1 2014, filed 12 May 2014.